Connor Bossi

Featured in:

Articles

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma

Aug 14, 2024 | medrxiv.org | Veronica Rendo |Eudocia Q. Lee |Nicholas Khuu |Connor Bossi

N.Y.R.A is key opinion leader for Bruker Daltonics, and receives support from Thermo Finnegan and EMD Serono. The other authors declare no competing financial interests. NCT03107780This study was sponsored by the Adult Brain Tumor Consortium (ABTC) NIH/NCI UM1 CA137443, NIH grants U54-CA210180 (NYRA), P41-EB028741 (NYRA), U19CA264504, R01CA262462 (RB and KL), R0188228 (RB and KL), and Capital Award from the Massachusetts Life Sciences Center.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.